Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Bad Is This News for Moderna?

TheMotleyFool

0 0

Moderna (NASDAQ: MRNA) and rival Pfizer (NYSE: PFE) dominate the coronavirus vaccine market. Here, I'm talking about vaccination for adults. But they're both vying for an additional market: the opportunity to vaccinate teens and kids.

Pfizer won authorization in the teen market in May. And the U.S. Food and Drug Administration (FDA) offered Pfizer authorization in kids ages 5 through 11 late last month. Moderna, however, has hit a stumbling block. The FDA says it needs more time to review the company's data in teens. And because of this, Moderna is delaying its regulatory request for use in kids. So, now you might be wondering: How bad is this news for Moderna? Let's find out.

Image source: Getty Images.

Source Fool.com

Like: 0

MRNA

Share